Illumina (ILMN)
(Delayed Data from NSDQ)
$139.02 USD
+10.04 (7.78%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $139.40 +0.38 (0.27%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$139.02 USD
+10.04 (7.78%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $139.40 +0.38 (0.27%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
Has Illumina (ILMN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
Illumina (ILMN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Illumina (ILMN) closed at $309.84, marking a +0.21% move from the previous day.
LGND vs. ILMN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LGND vs. ILMN: Which Stock Is the Better Value Option?
Align Technology-Benco Dental Deal to Expand iTero Reach
by Zacks Equity Research
Align Technology (ALGN) adopts initiatives to boost top-line contributions from iTero Intraoral scanners.
GNC Holdings to Expand Portfolio With Alani Nutrition Deal
by Zacks Equity Research
With Alani Nutrition being a women-focused supplement brand, it is believed that the partnership might help GNC Holdings (GNC) widen its customer base.
Tandem's Global Growth a Boost, Operating Losses a Bane
by Zacks Equity Research
Tandem's (TNDM) t:slim X2 Insulin Pump clinching a commercial license in Canada during Q4 is a tailwind.
GNC Forms Joint Venture With IVC to Improve Cost Efficiency
by Zacks Equity Research
The joint venture is set to manufacture the products produced by GNC Holdings' (GNC) Nutra manufacturing facility.
Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now
by Zacks Equity Research
Hologic's (HOLX) management is impressed with continued growth in the core Molecular Diagnostics sub-segment.
Hologic (HOLX) Receives Global Nods for Omni Hysteroscope
by Zacks Equity Research
Hologic's (HOLX) receipt of approvals for Omni Hysteroscope in Canada and Europe is expected to boost the GYN Surgical arm.
Here's Why You Should Snap Up Abbott (ABT) Stock Right Now
by Zacks Equity Research
Synergies from Alere consolidation in the form of revenues from Abbott's (ABT) Rapid Diagnostics business have been driving growth.
Here's Why You Should Invest in Illumina (ILMN) Stock Now
by Zacks Equity Research
Illumina (ILMN) continues to gain on solid international business.
Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y
by Zacks Equity Research
Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.
CBM or ILMN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CBM vs. ILMN: Which Stock Is the Better Value Option?
Illumina (ILMN) Q4 Earnings Lag Estimates, Revenues Top Mark
by Zacks Equity Research
Illumina's (ILMN) Q4 figures show a sturdy uptick in sequencing consumable revenues.
Here's Why You Should Snap Up Abbott (ABT) Stock Right Now
by Zacks Equity Research
We are optimistic about the strong and consistent performance of Abbott's (ABT) EPD segment. The company's Diabetes Care business has been hogging the limelight on strength in FreeStyle Libre.
Thermo Fisher (TMO) Down on Business Divestment Declaration
by Zacks Equity Research
Thermo Fisher's (TMO) Anatomical Pathology business comes under its Specialty Diagnostics segment catering to customers at healthcare and clinical laboratories.
Cerner (CERN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Cerner's (CERN) fourth-quarter 2018 results are likely to be hurt by year-over-year decline in bookings; Q4 guidance promising.
Will Core Business Units Boost McKesson's (MCK) Q3 Earnings?
by Zacks Equity Research
McKesson (MCK) expects to gain from solid segmental performances in third-quarter fiscal 2019.
Will Lower Revenues Dampen Juniper's (JNPR) Q4 Earnings?
by Zacks Equity Research
Juniper (JNPR) is likely to report lower year-over-year revenues in Q4 due to challenges in the market, particularly within the cloud vertical.
AmerisourceBergen (ABC) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
AmerisourceBergen's (ABC) first-quarter fiscal 2019 results are likely to gain from its core Pharmaceutical Distribution business unit.
Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now
by Zacks Equity Research
Strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets bode well for Tandem Diabetes (TNDM).
What's in Store for Edwards Lifesciences' (EW) Q4 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expected to see consistent performance by Surgical Structural Heart and Critical Care segments in Q4.
Will Top-Line Growth Support Corning's (GLW) Q4 Earnings?
by Zacks Equity Research
Corning (GLW) is likely to report higher year-over-year revenues in fourth-quarter 2018 on the back of healthy growth dynamics.
Will GPU Product Introduction Benefit AMD's Q4 Earnings?
by Zacks Equity Research
AMD Q4 results to benefit from GPU Product Rollouts & Partnerships
Will Flagship Impella Drive ABIOMED's (ABMD) Q3 Earnings?
by Zacks Equity Research
ABIOMED (ABMD) is likely to gain from flagship Impella in third-quarter fiscal 2019; positive trends in the CHD markets buoy optimism.